Objective:To investigate the effects of Yiqi Huoxue Tongguan Decoction on hemorheology, electrocardiogram, and peripheral blood expression of microRNA-155 and vasodilator-stimulated phosphoprotein (VASP) in patients with coronary heart disease and angina. Methods:A total of 102 patients with coronary heart disease and angina who were diagnosed and treated at the Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine from May 2023 to May 2024 were prospectively selected and randomly assigned into two groups using the envelope method. The control group ( n = 51) received conventional treatment, while the observation group ( n = 51) received Yiqi Huoxue Tongguan Decoction in addition to conventional treatment. The therapeutic effects of both groups were compared 4 weeks after treatment. Results:After treatment, the observation group showed significantly higher values for left ventricular ejection fraction [(57.48 ± 4.83)%], VASP [(385.95 ± 87.44) ng/L], and stroke volume [(78.96 ± 4.77) mL] compared with the control group [(52.22 ± 4.26)%, (339.85 ± 84.47) ng/L, (73.89 ± 5.14) mL, t = 5.83, 2.71, 5.16, all P < 0.05]. In addition, the observation group had significantly lower values for platelet aggregation rate [(32.32 ± 6.82)%], microRNA-155 (0.24 ± 0.05), plasma viscosity [(1.32 ± 0.29) mPa·s], whole blood high shear viscosity [(4.11 ± 0.77) mPa·s], interleukin-6 [(16.45 ± 3.81) μg/L], fibrinogen [(3.12 ± 0.77) g/L], high-sensitivity C-reactive protein [(9.85 ± 2.15) mg/L], and left ventricular end-systolic diameter [(36.25 ± 3.59) mm] compared with the control group ( t = 5.90, 4.86, 3.64, 3.31, 9.58, 3.95, 7.25, 6.23, all P < 0.05). The observation group also had a lower traditional Chinese medicine syndrome score [(9.52 ± 1.04) points], fewer angina attacks per week [(3.24 ± 0.71) times/week], and shorter attack duration [(2.54 ± 1.06) min/attack] compared with the control group [(12.76 ± 1.55) points, (4.56 ± 0.94) times/week, (4.26 ± 1.14) min/attack, t = 12.40, 0.20, 7.89, all P < 0.001]. The observation group showed significantly better electrocardiogram outcomes than the control group ( Z = 2.76, P = 0.006). Conclusions:Yiqi Huoxue Tongguan Decoction for the treatment of coronary heart disease and angina can regulate the expression of inflammatory factors, microRNA-155, and VASP, improve hemorheology and cardiac function, and reduce the frequency of angina attacks.

Objective:To investigate the effects of Yiqi Huoxue Tongguan Decoction on hemorheology, electrocardiogram, and peripheral blood expression of microRNA-155 and vasodilator-stimulated phosphoprotein (VASP) in patients with coronary heart disease and angina. Methods:A total of 102 patients with coronary heart disease and angina who were diagnosed and treated at the Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine from May 2023 to May 2024 were prospectively selected and randomly assigned into two groups using the envelope method. The control group ( n = 51) received conventional treatment, while the observation group ( n = 51) received Yiqi Huoxue Tongguan Decoction in addition to conventional treatment. The therapeutic effects of both groups were compared 4 weeks after treatment. Results:After treatment, the observation group showed significantly higher values for left ventricular ejection fraction [(57.48 ± 4.83)%], VASP [(385.95 ± 87.44) ng/L], and stroke volume [(78.96 ± 4.77) mL] compared with the control group [(52.22 ± 4.26)%, (339.85 ± 84.47) ng/L, (73.89 ± 5.14) mL, t = 5.83, 2.71, 5.16, all P < 0.05]. In addition, the observation group had significantly lower values for platelet aggregation rate [(32.32 ± 6.82)%], microRNA-155 (0.24 ± 0.05), plasma viscosity [(1.32 ± 0.29) mPa·s], whole blood high shear viscosity [(4.11 ± 0.77) mPa·s], interleukin-6 [(16.45 ± 3.81) μg/L], fibrinogen [(3.12 ± 0.77) g/L], high-sensitivity C-reactive protein [(9.85 ± 2.15) mg/L], and left ventricular end-systolic diameter [(36.25 ± 3.59) mm] compared with the control group ( t = 5.90, 4.86, 3.64, 3.31, 9.58, 3.95, 7.25, 6.23, all P < 0.05). The observation group also had a lower traditional Chinese medicine syndrome score [(9.52 ± 1.04) points], fewer angina attacks per week [(3.24 ± 0.71) times/week], and shorter attack duration [(2.54 ± 1.06) min/attack] compared with the control group [(12.76 ± 1.55) points, (4.56 ± 0.94) times/week, (4.26 ± 1.14) min/attack, t = 12.40, 0.20, 7.89, all P < 0.001]. The observation group showed significantly better electrocardiogram outcomes than the control group ( Z = 2.76, P = 0.006). Conclusions:Yiqi Huoxue Tongguan Decoction for the treatment of coronary heart disease and angina can regulate the expression of inflammatory factors, microRNA-155, and VASP, improve hemorheology and cardiac function, and reduce the frequency of angina attacks.

Objective:To investigate the effects of Ureaplasma urealyticum GrpE ( Uu-GrpE) on the maturation of dendritic cells and the polarization of T cells. Methods:Uu-GrpE was expressed and purified, and then identified by Western blot. The cytotoxicity of Uu-GrpE to mouse bone marrow-derived dendritic cells (BMDCs) was analyzed by LDH kit. After stimulating BMDCs with Uu-GrpE, the expression of costimulatory molecules, CD80, CD86 and major histocompatibility complex Ⅱ (MHCⅡ), on the surface of BMDCs was detected by flow cytometry, and ELISA was used to detect the cytokines such as IL-12p70, TNF-α, IL-1β and IL-6. CD4 + Na?ve T cells were isolated from mouse spleen tissues by magnetic beads. A co-culture system of BMDCs and Na?ve T cells was constructed to analyze the effects of GrpE-stimulated mature BMDCs (GrpE-BMDCs) on T cell proliferation and polarization towards Th1/Th2. Mice were immunized with GrpE-BMDCs through the tail vein, and the induced humoral and cellular immune responses were detected by ELISA and flow cytometry. Results:Uu-GrpE was successfully express and high purity BMDCs were isolated. Uu-GrpE could stimulate BMDCs to secrete cytokines such as IL-12p70, TNF-α, IL-1β and IL-6 without having cytotoxicity. Uu-GrpE significantly increased the expression of CD80 [mean flourscence indensity (MFI): (324.00±22.11) vs (91.03±10.95), P<0.01], CD86 [MFI: (1 176.00±51.39) vs (217.00±14.93), P<0.01] and MHCⅡ [MFI: (708.70±56.32) vs (185.70±16.77), P<0.01] on BMDCs. Compared to the GrpE-BMDCs only group and GrpE (boiled)-BMDCs+ T cell group, the GrpE-BMDCs+ T cell group showed significantly increased T cell proliferation [stimulation index: (7.25±0.21) vs(6.55±0.23) and (6.09±0.35), both P<0.05], and dramatically promoted T cell secretion of IL-2 and IFN-γ [IL-2: (145.60±14.67) pg/ml vs(55.92±3.12) pg/ml and (26.05±2.40) pg/ml, P<0.05 and P<0.01; IFN-γ: (267.20±37.80) pg/ml vs(146.70±20.65) pg/ml and(27.84±6.69) pg/ml, both P<0.05]. However, no significant change was observed in the expression of Th2-type cytokines. Moreover, the adoptive transfer of GrpE-BMDCs induced a Th1-type immune response. Conclusions:Uu-GrpE could stimulate the maturation and polarization of BMDCs. Moreover, it could induce Th1 immune response as a candidate protein vaccine for Ureaplasma urealyticum.

Spliceosomal dysfunction plays a major role in pathogenesis of myelodysplastic syndrome (MDS). Splicing factor somatic mutations, including SF3B1, U2AF1 (U2AF35), SRSF2, ZRSR2, PRPF40B, SF1, SF3A1, and U2AF2, comprise a common (45%–85%) class of mutated genes in MDS. These genes exist in a mutually exclusive manner at the 3'splice site of mRNA processing and are predomi-nantly heterozygous and missense. RNA splicing might have therapeutic and prognosis values in MDS. This review mainly describes the pathogenesis of common splicing factor gene mutations in MDS and discusses possible therapeutic implications, clinical analysis, and prognosis.

BACKGROUND: Eye acupuncture therapy is a technique used to adjust qi-blood circulation, relax muscles and tendons, and activate col aterals by acupuncture at the acupoints around the eye bal s and in the orbital border. This therapy has been widely used in the clinic because it exhibits remarkable therapeutic effects on many ischemic cerebrovascular diseases. However, the precise mechanism behind this therapy remains poorly understood. Neurotrophic factors are a protein family including neurotrophic factors and brain-derived neurotrophic factors that can regulate neuronal survival, development and functioning.
OBJECTIVE: To investigate the effects of eye acupuncture therapy on neurological function and nerve growth factor and brain-derived neurotrophic factor expression in the brain tissue of rat models of cerebral ischemia/reperfusion injury.
METHODS: Fifty-four male Sprague-Dawley rats were randomly divided into three groups with 18 rats per group: sham-operated, model and eye acupuncture therapy groups. Rat models of middle cerebral artery occlusion were established by the intraluminal suture method in the model and eye acupuncture therapy groups. Eye acupuncture was performed at the fol owing acupoints liver area, upper-jiao area, lower-jiao area and kidney area located at the internal orbital margin at 2 hours after cerebral ischemia/reperfusion injury. Rat neurological function was evaluated at 3, 7, and 14 days after injury. Nerve growth factor and brain-derived neurotrophic factor expression in the rat brain tissue was detected using immunohistochemical staining method at 1 and 2 weeks after treatment. Cerebral infarct size was determined using TTC staining at 2 weeks after treatment.
RESULTS AND CONCLUSION: (1) At 1 and 2 weeks after injury, nerve growth factor and brain-derived neurotrophic factor expression was significantly greater in the eye acupuncture therapy group than in the model group (P < 0.05), but nerve growth factor and brain-derived neurotrophic factor expression in the eye acupuncture therapy group was decreased at 2 weeks after injury compared to that at 1 week after injury. (2) At 7 and 14 days after treatment, neurological function scores in the eye acupuncture therapy group were significantly lowered, and there was significant difference between eye acupuncture therapy and model groups (P < 0.05), but they were significantly higher than those in the sham-operated group (P< 0.05). (3) At 2 weeks after treatment, cerebral infarct size was significantly greater in the eye acupuncture therapy and model groups than in the sham-operated group (P < 0.01), and it was significantly smal er in the eye acupuncture therapy group than in the model group (P < 0.05). (4)These results indicate that eye acupuncture therapy shows neuroprotective effects on ischemic cerebral injury by increasing nerve growth factor and brain-derived neurotrophic factor expression, improving neurological function, and reducing cerebral infarct size.